✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Venus Remedies Ltd.

VENUSREM

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹600 Cr.
P/E
11.17

Venus Remedies Ltd.

  • Venus Remedies
  • Prevest Denpro
  • Medicamen Biotech

FAQs on Venus Remedies Ltd. Shareprice

Venus Remedies has given lower returns compared to its competitors.
Venus Remedies has grown at ~-3.29% over the last 4yrs while peers have grown at a median rate of 18.78%

Venus Remedies is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Venus Remedies is 11.17, while 3 year average PE is 12.44.
Also latest EV/EBITDA of Venus Remedies is 8.36 while 3yr average is 7.19.

View FAQ's On Business

Growth Table

  • Venus Remedies Ltd.
  • Prevest Denpro
  • Medicamen Biotech

Balance Sheet

  • Venus Remedies Ltd.
  • Prevest Denpro
  • Medicamen Biotech

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Venus Remedies Ltd.
  • Prevest Denpro
  • Medicamen Biotech

Cash Flow

  • Venus Remedies Ltd.
  • Prevest Denpro
  • Medicamen Biotech

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Venus Remedies Ltd.
  • Prevest Denpro
  • Medicamen Biotech

Quarterly Results

  • Venus Remedies Ltd.
  • Prevest Denpro
  • Medicamen Biotech

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Venus Remedies Ltd. Financials

Balance sheet of Venus Remedies is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Venus Remedies is decreasing.
Latest net debt of Venus Remedies is -₹158.4 Crs as of Mar-25.
This is less than Mar-24 when it was -₹94.71 Crs.

Yes, profit is increasing.
The profit of Venus Remedies is ₹53.71 Crs for TTM, ₹45.31 Crs for Mar 2025 and ₹28.49 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Venus Remedies latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech